Zentalis prices $80.5 million stock offering at $3.50 a share
The clinical-stage biopharma will sell 23 million shares to help fund its WEE1 inhibitor azenosertib through ongoing ovarian cancer trials.
SEC filing (2)
Latest
2 stories
Friday, August 14
Thursday, August 6
Zentalis reports Q2 2026 results as DENALI Part 2 nears full enrollment
The company said its accelerated approval strategy for azenosertib remains intact after FDA discussions, with topline DENALI Part 2 data expected in 1H 2027.
Drugs@FDA, SEC filing (2)